Alimera Sciences Appoints David Dyer as Chief Retina Specialist
May 17, 2021 at 01:12 pm
Share
Alimera Sciences, Inc. has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective May 17, 2021. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri. Dr. Dyer founded Retina Associates, LLC in 1999, one of the most well-established and advanced practices devoted to diagnosing and treating diseases of the retina, macula, and vitreous in the Greater Kansas City area and the surrounding communities. Dr. Dyer also founded TreVia Digital Health, LLC, a health care company that provides technology-enabled services, including digital diabetic retinopathy screenings, for the diagnosis and prevention of diabetic retinopathy complications and iTronix Systems, LLC a medical device development company.
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by laser photocoagulation, a retinal procedure in which a laser is used to apply a burn.